← ANALYST RATINGS · TIPRANKS
Candel Therapeutics (CADL): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $20.80, the highest $25.00, the lowest $16.00. The average is +154.0% from the last price of $8.19.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 → $9.00−5.3% | Hold | +9.9% | Reiterated | 16.10.26on TipRanks 14:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.50 → $9.00−5.3% | Hold | +9.9% | Reiterated | 15.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 → $9.00−5.3% | Hold | +9.9% | Reiterated | 15.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 → $9.00−5.3% | Hold | +9.9% | Reiterated | 15.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $9.00−5.3% | Hold | +9.9% | Reiterated | 15.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $9.00−21.7% | Hold | +9.9% | Reiterated | 14.10.26on TipRanks 02:05 | — | |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $18.00 | Buy | +119.8% | Reiterated | 30.09.26on TipRanks Oct 1 05:09 | −3.8%next day −2.9% · 5 days −7.9% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $23.00 | Buy | +180.8% | Reiterated | 30.09.26on TipRanks 12:55 | −3.8%next day −2.9% · 5 days −7.9% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $16.00 | Buy | +95.4% | Reiterated | 14.08.26on TipRanks 11:05 | −0.5%next day +4.2% · 5 days +13.4% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $22.00 | Buy | +168.6% | Reiterated | 14.08.26on TipRanks 07:30 | −0.5%next day +4.2% · 5 days +13.4% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $25.00 | Buy | +205.3% | Reiterated | 13.08.26on TipRanks 07:15 | +9.8%next day −0.5% · 5 days +6.6% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $26.00 | Buy | +217.5% | Reiterated | 30.06.26on TipRanks Jul 2 02:35 | −1.4%next day −3.9% · 5 days −3.9% | ↗ |
| Unknown Analyst | Cantor Fitzgerald | $30.00 | Buy | +266.3% | Initiated | 20.04.26on TipRanks 07:06 | +13.5%next day −2.4% · 5 days −13.8% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $15.00 | Buy | +83.2% | Initiated | 28.10.25on TipRanks 07:30 | +3.4%next day −2.0% · 5 days −6.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Candel Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.80 at a price of $10.44 (+99.2%); now: $20.80 at $8.19 (+154.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 6 | 7 | 7 | 9 | 7 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 3 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.35 (from $-0.56 to $-0.22). Last quarter: $-0.52.
Best top-analyst consensus in the sector · Healthcare
About Candel Therapeutics
- CEO: Paul-Peter Tak
- Employees: 55
- 117 Kendrick Street, Needham, MA, 02494, US
- www.candeltx.com
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Data from the stock’s TipRanks forecast page, read 149 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗